GRAIL said CEO Bob Ragusa will retire effective June 1, 2026, with President Josh Ofman, MD, MSHS, succeeding him as chief executive, according to the company. Ofman was appointed to GRAIL's board of directors on March 12. Board Chairman Greg Summe described the change as the culmination of a long-term succession planning process. Ragusa will remain on the board until June 1 and serve in a senior advisory role through March 2027.
The announcement comes days after GRAIL's Galleri multi-cancer early detection test failed to meet its primary endpoint in the NHS-Galleri trial, an outcome that raised questions about the test's pathway to broad reimbursement. The company also recently announced integration of Galleri into Epic's electronic health record platform, giving the test access to a network covering more than 300 million patient records.
GRAIL credited Ragusa with leading the company through its spinout from Illumina, driving commercial growth, and scaling laboratory operations in North Carolina. Ofman was described as having played a central role in shaping strategy, advancing Galleri's evidence program, and strengthening clinical, regulatory, and policy engagement.
The transition positions Ofman — whose background centers on evidence generation and market access — to address the reimbursement challenges highlighted by the NHS trial outcome. Whether the full NHS-Galleri data, once published, show a narrow statistical shortfall or a more fundamental limitation will determine GRAIL's ability to secure population-level coverage from CMS and commercial payers.